<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Rousseaux MWC</submitter><funding>NICHD NIH HHS</funding><funding>NINDS NIH HHS</funding><funding>CIHR</funding><pagination>9286-9301</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6199406</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>38(43)</volume><pubmed_abstract>Accumulation of α-Synuclein (α-Syn) causes Parkinson's disease (PD) as well as other synucleopathies. α-Syn is the major component of Lewy bodies and Lewy neurites, the proteinaceous aggregates that are a hallmark of sporadic PD. In familial forms of PD, mutations or copy number variations in &lt;i>SNCA&lt;/i> (the α-Syn gene) result in a net increase of its protein levels. Furthermore, common risk variants tied to PD are associated with small increases of &lt;i>wild-type&lt;/i> α-Syn levels. These findings are further bolstered by animal studies which show that overexpression of α-Syn is sufficient to cause PD-like features. Thus, increased α-Syn levels are intrinsically tied to PD pathogenesis and underscore the importance of identifying the factors that regulate its levels. In this study, we establ</pubmed_abstract><journal>The Journal of neuroscience : the official journal of the Society for Neuroscience</journal><pubmed_title>A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation Approach.</pubmed_title><pmcid>PMC6199406</pmcid><funding_grant_id>R21 NS096395</funding_grant_id><funding_grant_id>U54 HD083092</funding_grant_id><funding_grant_id>R21 NS089854</funding_grant_id><pubmed_authors>Jeong HH</pubmed_authors><pubmed_authors>Kim JJ</pubmed_authors><pubmed_authors>Shulman JM</pubmed_authors><pubmed_authors>Xu Q</pubmed_authors><pubmed_authors>Elledge SJ</pubmed_authors><pubmed_authors>Revelli JP</pubmed_authors><pubmed_authors>Westbrook TF</pubmed_authors><pubmed_authors>Bajic A</pubmed_authors><pubmed_authors>Li MZ</pubmed_authors><pubmed_authors>Kang H</pubmed_authors><pubmed_authors>Liu Z</pubmed_authors><pubmed_authors>Lavery LA</pubmed_authors><pubmed_authors>Zoghbi HY</pubmed_authors><pubmed_authors>Rousseaux MWC</pubmed_authors><pubmed_authors>Kim JY</pubmed_authors><pubmed_authors>Al-Ramahi I</pubmed_authors><pubmed_authors>Botas J</pubmed_authors><pubmed_authors>Phan ET</pubmed_authors><pubmed_authors>Perez AM</pubmed_authors><pubmed_authors>Vazquez-Velez GE</pubmed_authors><pubmed_authors>Deger JM</pubmed_authors><pubmed_authors>Ye H</pubmed_authors></additional><is_claimable>false</is_claimable><name>A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation Approach.</name><description>Accumulation of α-Synuclein (α-Syn) causes Parkinson's disease (PD) as well as other synucleopathies. α-Syn is the major component of Lewy bodies and Lewy neurites, the proteinaceous aggregates that are a hallmark of sporadic PD. In familial forms of PD, mutations or copy number variations in &lt;i>SNCA&lt;/i> (the α-Syn gene) result in a net increase of its protein levels. Furthermore, common risk variants tied to PD are associated with small increases of &lt;i>wild-type&lt;/i> α-Syn levels. These findings are further bolstered by animal studies which show that overexpression of α-Syn is sufficient to cause PD-like features. Thus, increased α-Syn levels are intrinsically tied to PD pathogenesis and underscore the importance of identifying the factors that regulate its levels. In this study, we establ</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Oct</publication><modification>2026-04-07T15:23:01.63Z</modification><creation>2019-06-06T22:45:52Z</creation></dates><accession>S-EPMC6199406</accession><cross_references><pubmed>30249792</pubmed><doi>10.1523/JNEUROSCI.0254-18.2018</doi><doi>10.1523/jneurosci.0254-18.2018</doi></cross_references></HashMap>